SCHEMBL30740841

SCHEMBL30740841

Cc1ccc(OCc2cccc(CC3CCCCN3C(=O)OC(C)(C)C)n2)c(CO)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ PRMT5 O14744 1/20 0.38
▸ CHEK2 O96017 1/20 0.37
▸ METTL3 Q86U44 1/20 0.37
▸ HCRTR2 O43614 4/20 0.36
▸ HCRTR1 O43613 3/20 0.36
▸ GPR119 Q8TDV5 2/20 0.36
▸ KDM1A O60341 1/20 0.36
▸ PDE8B O95263 1/20 0.36
▸ ALOX5AP P20292 1/20 0.36
▸ FEN1 P39748 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ DPP4 P27487 1/20 0.36
▸ F2RL3 Q96RI0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30740694 0.87 HCRTR2 (0.41) L3MBTL1NPSR1LMNAMAPTPRMT5
SCHEMBL30740738 0.87 PRMT5 (0.38) L3MBTL1NPSR1LMNAMAPTPRMT5
SCHEMBL29826235 0.84 GPR119 (0.45) LMNAGPR119
SCHEMBL30740781 0.83 KDM1A (0.44) NPSR1LMNAMAPTPRMT5CHEK2
SCHEMBL30740732 0.81 MRGPRX4 (0.45) LMNAPRMT5CHEK2GPR119KDM1A
SCHEMBL30740850 0.72 CHEK2 (0.42) PRMT5CHEK2METTL3HCRTR2HCRTR1
SCHEMBL29826374 0.71 GPR119 (0.43) LMNAMAPTGPR119
SCHEMBL29826499 0.71 GPR119 (0.46) LMNAGPR119
SCHEMBL2512853 0.70 METTL3 (0.45) L3MBTL1NPSR1LMNAMAPTPRMT5
SCHEMBL17979996 0.70 ALOX5AP (0.47) HCRTR2HCRTR1GPR119ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117043154-A GPCR receptor agonists, pharmaceutical compositions comprising same, and methods of use thereof 卡莫特医疗有限公司 2023-11-10 — — CN disclosed
Send feedback